Wednesday, January 28, 2026 1/28/2026

Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis

Award Number: R01AA028190
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2026

Group Awards By:

View Award Description

Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis - Abstract Despite poor clinical outcomes there has been very limited response to therapies targeting hepatic inflammatory response especially in patients with malnutrition. Sarcopenia or skeletal muscle loss is a major component of malnutrition in AH and adversely affects clinical outcomes in these patients. Potential mechanisms by which sarcopenia can aggravate AH include reduced skeletal muscle metabolism of ethanol and impaired ammonia disposal due to decreased hepatic ureagenesis promoting ammonia induced hepatotoxicity. Even though targeting sarcopenia is an innovative approach with a mechanistic rationale to improve outcomes in patients with AH, this is not part of the therapeutic strategy in the ongoing NIAAA funded AlcHep network. Our published and preliminary data show dysregulated skeletal muscle protein homeostasis or proteostasis in response to ethanol in myotubes, mouse models, and human patients with alcoholic liver disease including AH. We also observed that ethanol exposure increases the skeletal muscle sensitivity to lipopolysaccharide (LPS) that results in impaired protein synthesis and increased autophagy and consequent sarcopenia. Interestingly, expression of canonical LPS receptor, TLR4, is increased in myotubes and in muscles from mice exposed to ethanol and patients with alcoholic liver disease. Consistently, P65NFkB, a downstream target of TLR4, is activated with increased. Expression of myostatin, a TGFβ superfamily member, a known transcriptional target of P65NFkB and negative regulator of skeletal muscle protein synthesis is also increased with LPS and ethanol. Interestingly, low molecular weight hyaluronic acid, especially fragments 35Kd and lower (HA35) have been reported to inhibit or modulate TLR4 signaling via specific receptors in a context specific manner. We made a novel observation that HA35 reversed ethanol and LPS induced reduction in myotube diameter, impaired proteostasis and signaling perturbations in both myotubes and mice exposed to ethanol. We will use HA35 initially in myotubes exposed to ethanol and mice chronically fed ethanol with binge (Gao model) that has significant sarcopenia and liver injury similar to that in human AH. In these preclinical studies, we will determine the molecular mechanisms by which HA35 reverses sarcopenia in AH. We will study the tissue responses to HA35 in ethanol-fed mice including skeletal muscle protein synthesis and breakdown and signaling responses. We will translate our preliminary and preclinical data into clinical application by treating human subjects with HA35, a food supplement, following acute ethanol exposure. We will also test if HA35 is beneficial in patients with moderate AH, a group of patients for whom there are currently no therapies available despite significant muscle loss and there are no ongoing clinical trials in moderate AH in the Alchep network. A data coordinating center will assist with these human studies. These studies will permit rapid therapeutic translation of our studies using HA35 as a novel, mechanism-based therapy for sarcopenia in AH, currently a major unmet need in this patient population.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	000	5	1/14/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $553,183 )
2024	2024	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	000	5	7/24/2024	NON-COMPETING CONTINUATION	$553,183
														Subtotal = $553,183

Issue Date FY: 2023 ( Subtotal = $554,644 )
2023	2023	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE OF CASE WESTERN RESERVE UNIVERSITY	9500 EUCLID AVE.	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	000	4	8/1/2023	NON-COMPETING CONTINUATION	$554,644
														Subtotal = $554,644

Issue Date FY: 2022 ( Subtotal = $557,780 )
2022	2022	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	000	3	8/2/2022	NON-COMPETING CONTINUATION	$557,780
														Subtotal = $557,780

Issue Date FY: 2021 ( Subtotal = $557,780 )
2021	2021	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	001	2	7/23/2021	NON-COMPETING CONTINUATION	$557,780
2021	2020	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	000	1	6/30/2021	NEW	$0
														Subtotal = $557,780

Issue Date FY: 2020 ( Subtotal = $557,780 )
2020	2020	CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE/CWRU	9500 EUCLID AVE	CLEVELAND	OH	44195	CUYAHOGA	USA	Alcohol Research Programs	000	1	9/24/2020	NEW	$557,780
														Subtotal = $557,780

Grand Total All Awards = $2,781,167

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis

Award Number: R01AA028190

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer